Arimappamagan Arivazhagan
National Institute of Mental Health and Neurosciences(IN)
Publications by Year
Research Areas
Glioma Diagnosis and Treatment, Meningioma and schwannoma management, MicroRNA in disease regulation, Epilepsy research and treatment, Vascular Malformations Diagnosis and Treatment
Most-Cited Works
- → Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance(2017)652 cited
- → Insulin Growth Factor-2 Binding Protein 3 (IGF2BP3) Is a Glioblastoma-specific Marker That Activates Phosphatidylinositol 3-Kinase/Mitogen-activated Protein Kinase (PI3K/MAPK) Pathways by Modulating IGF-2(2011)157 cited
- → Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis(2010)128 cited
- → Methylation Silencing of ULK2, an Autophagy Gene, Is Essential for Astrocyte Transformation and Tumor Growth(2014)97 cited
- → miR-219-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in Glioblastoma(2013)89 cited
- → Grade-Specific Expression of Insulin-like Growth Factor–Binding Proteins-2, -3, and -5 in Astrocytomas: IGFBP-3 Emerges as a Strong Predictor of Survival in Patients with Newly Diagnosed Glioblastoma(2010)87 cited
- → Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis(2015)82 cited
- → A DNA Methylation Prognostic Signature of Glioblastoma: Identification of NPTX2-PTEN-NF-κB Nexus(2013)77 cited
- → Proteomic Identification of Haptoglobin α2 as a Glioblastoma Serum Biomarker: Implications in Cancer Cell Migration and Tumor Growth(2010)76 cited
- → Serum biomarkers identification by iTRAQ and verification by MRM: S100A8/S100A9 levels predict tumor-stroma involvement and prognosis in Glioblastoma(2019)64 cited